RESUMEN
Monoclonal antibody (mAb) therapeutics have tremendous potential to benefit patients with lung diseases, for which there remains substantial unmet medical need. To capture the current state of mAb research and development in the area of respiratory diseases, the Research Center of Respiratory Diseases (CEPR-INSERM U1100), the Laboratory of Excellence "MAbImprove," the GDR 3260 "Antibodies and therapeutic targeting," and the Grant Research program ARD2020 "Biotherapeutics" invited speakers from industry, academic and government organizations to present their recent research results at the Therapeutic Monoclonal Antibodies for Respiratory Diseases: Current challenges and perspectives congress held March 31 - April 1, 2016 in Tours, France.
Asunto(s)
Anticuerpos Monoclonales/uso terapéutico , Enfermedades Respiratorias/terapia , Administración por Inhalación , Anticuerpos Monoclonales/administración & dosificación , Terapia Biológica/métodos , Terapia Biológica/tendencias , HumanosRESUMEN
BACKGROUND: The lung comprises an interesting route of administration not only for topical drugs but also for systemically acting drugs. Over the last years, several models have been developed in order to study the efficacy and safety of pulmonary drug delivery. OBJECTIVE: This review describes relevant drug delivery models for preclinical evaluation of inhaled drug products. METHODS: Epithelial cell culture models, the isolated perfused lung and in vivo models are reviewed. The suitability and limitations of each method are discussed. This review is mostly based on publications from the last 10 years. RESULTS/CONCLUSION: Cell cultures are ideal models to compare transport rates of molecules and to study their mechanisms of transepithelial transport. Yet the most complete assessment of pulmonary drug delivery including delivery efficacy and safety remains provided by studies performed in vivo in animal models.